Carregando...
Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis
Alemtuzumab is a selective humanized monoclonal antibody directed against the CD52 antigen, and has been found to be a powerful treatment for relapsing remitting multiple sclerosis. Alemtuzumab demonstrated high efficacy in several clinical studies. The risk of relapse and sustained accumulation of...
Na minha lista:
| Publicado no: | Ther Clin Risk Manag |
|---|---|
| Principais autores: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2017
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5522829/ https://ncbi.nlm.nih.gov/pubmed/28761351 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TCRM.S134398 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|